Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL201 + serplulimab + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**YL201 + serplulimab + platinum-based chemotherapy** is a multi-agent combination regimen used in oncology clinical trials, primarily for first-line treatment of lung cancers. It combines: - **YL201** (no detailed information on modality or mechanism in search results; process notes below) - **Serplulimab**, a monoclonal antibody against programmed death protein 1 (PD-1), which acts as an immune checkpoint inhibitor. - **Platinum-based chemotherapy**, typically carboplatin plus etoposide or nab-paclitaxel (as described in ASTRUM trials), which are standard cytotoxic chemotherapeutics. Serplulimab blocks the PD-1 pathway, enhancing T cell-mediated anti-tumor immunity[3][1]. Platinum agents induce DNA crosslinking and apoptosis in rapidly dividing cancer cells. The combination has demonstrated superior efficacy over chemotherapy alone in extensive-stage small cell lung cancer (ES-SCLC)[1][3][4] and advanced squamous non-small cell lung cancer (NSCLC)[2].
- Other names
- YL201 + serplulimab + platinum-based chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)B7-H3DNA
Beyond the preview
Go deeper on YL201 + serplulimab + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL201 + serplulimab + platinum-based chemotherapy.